ImmunityBio vs Rhythm Pharmaceuticals

ImmunityBio (IBRX), health care, and Rhythm Pharmaceuticals (RYTM), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Rhythm Pharmaceuticals is worth $8.1B on the stock market and ImmunityBio $6.7B: Rhythm Pharmaceuticals is valued at 21% more. ImmunityBio's operating margin in its latest fiscal year was -226% and Rhythm Pharmaceuticals's -101%. Over the past year ImmunityBio's share price has moved +185% and Rhythm Pharmaceuticals's +6.93%.

Key facts

ImmunityBio market value
$6.7B
Rhythm Pharmaceuticals market value
$8.1B
ImmunityBio revenue
$113.3MFY to 2025-12-31
Rhythm Pharmaceuticals revenue
$189.8MFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

ImmunityBio vs Rhythm Pharmaceuticals: every measure side by side
Measure ImmunityBio Rhythm Pharmaceuticals
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$6.7Blower$8.1Bhigher
Revenue$113.3Mlower$189.8Mhigher
Earnings-$351.4Mlower-$196.5Mhigher
Employees684higher414lower
Total assets$501.9Mhigher$480.2Mlower
Valuation
P/E——
P/S58.8higher42.6lower
P/B—91.9
Dividend yield0.00%0.00%
Profitability
Operating margin-226%lower-101%higher
Balance sheet
Net assets-$500.5Mlower$139.1Mhigher
Total liabilities$1Bhigher$210.2Mlower
Total debt—$108.2M
Cash on hand$88.3Mhigher$54.3Mlower
Price change
Today+4.68%lower+8.49%higher
1 year+185%higher+6.93%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

ImmunityBio only (0)

None of the tracked investors.

Percentages are each holding's share of that investor's reported portfolio. · Who owns RYTM

Further comparisons

Learn

Questions and answers

Which is bigger, ImmunityBio or Rhythm Pharmaceuticals?

By market value, Rhythm Pharmaceuticals is the larger: $8.1B against $6.7B for ImmunityBio. By revenue in its latest fiscal year, Rhythm Pharmaceuticals is the larger: $189.8M against $113.3M for ImmunityBio.

Which has the higher operating margin?

Rhythm Pharmaceuticals: -101%, against -226% for ImmunityBio. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which superinvestors own both ImmunityBio and Rhythm Pharmaceuticals?

None of the tracked superinvestors holds both in their latest 13F filing. 0 hold ImmunityBio and 4 hold Rhythm Pharmaceuticals.

Cite this page

Funkfolio, “ImmunityBio vs Rhythm Pharmaceuticals”, data as of 17 November 2026. https://funkfolio.com/compare/ibrx-vs-rytm

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.